Article thumbnail

Vascular Damage in Kidney Disease: Beyond Hypertension

By Andréa E. M. Stinghen and Roberto Pecoits-Filho

Abstract

Chronic kidney disease (CKD) is highly prevalent and a multiplier of cardiovascular disease (CVD) and cannot be completely explained by traditional Framinghan risk factors. Consequently, greater emphasis has been placed in nontraditional risk factors, such as inflammation, endothelial dysfunction, sympathetic overactivation, protein-energy wasting oxidative stress, vascular calcification, and volume overload. The accumulation of uremic toxins (and the involvement of genetic factors) is responsible for many of the clinical consequences of a condition known as uremia. In this brief paper, we discuss mechanisms involved in the vascular damage of CKD patients, aiming to point out that important factors beyond hypertension are largely responsible for endothelial activation and increased CVD risk, with potential impact on risk stratification and development of novel therapeutic options

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier: oai:pubmedcentral.nih.gov:3160729
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). A .A .H o u s e ,M .H a a p i o ,J .L a s s u s ,R .B e l l o m o ,a n dC .R o n c o , “Therapeutic strategies for heart failure in cardiorenal syndromes,”
  2. (2010). A .B .H a u s e r ,I .R .A z e v e d o ,S .G o n c a l v e s ,A .S t i n g h e n ,C .A i t a , andR.Pecoits-Filho,“Sevelamercarbonatereduces inflammation and endotoxemia in an animal model of uremia,”
  3. (2009). A .E .S t i n g h e n ,S .M .G o n c a l v e s ,E .G .M a r t i n e se ta l . ,“ I n -creased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease,”
  4. (2010). A gut feeling on endotoxemia: causes andconsequences inchronickidneydisease,”Nephron Clinical Practice,
  5. a n h o l d e r ,S .V a nL a e c k e ,a n dG .G l o r i e u x ,“ W h a ti sn e w
  6. (2008). a n h o l d e r ,U .B a u r m e i s t e r ,P .B r u n e t ,G .C o h e n ,G .G l o -rieux, and
  7. (2007). a r b i e r i ,A .B a j e t t o ,C .P o r c i l l e ,A .P a t t a r o z z i ,G .S c h e t
  8. (2004). Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovasculardisease,”CongestiveHeart Failure,
  9. (2006). Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients,”
  10. (2005). Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study,”
  11. (2000). B o g e r ,S .M .B o d e - B o g e r ,K .S y d o w ,D .D .H e i s t a d ,a n d
  12. (2010). Cardio-kidney-damage: a unifying concept,”
  13. (2003). Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice,”
  14. (2008). Dialysis-related systemic microinflammation is associated with specific genomic patterns,”
  15. (2010). disease:apublic health priority and harbinger of premature cardiovascular disease,”
  16. (2011). Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?”
  17. (2008). Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?”
  18. (2006). Endothelial health and diversity in the kidney,”
  19. (2005). Endotheliumdependent contractions in hypertension,”
  20. (2007). Folate and ApoE DNA methylation induced by homocysteine in human monocytes,”
  21. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia,” The Lancet,
  22. (2010). Genome-wide association studies in nephrology research,”
  23. (2003). Glorieux et al., “Review on uremic toxins: classification, concentration, and interindividual variability,”Kidney
  24. (2009). Hypermethylation of estrogen receptor-α gene in atheromatosis patients and its correlation with homocysteine,”
  25. (2008). J.Ekstrom,“Epigenetics—a helpful toolto better understand processes in clinical nephrology?”
  26. J.Malyszko,“Mechanism of endothelialdysfunction in chronic kidney disease,”
  27. (2010). Karin,“The multiple faces ofCXCL12 (SDF-1α)i nt h er e g -ulation of immunity during health and disease,”
  28. (2010). M e i j e r s ,K .C l a e s ,B .B a m m e n se ta l . ,“ p—and cardiovascular risk in mild-to-moderate kidney disease,” Clinical J o u r n a lo ft h eA m e r i c a nS o c i e t yo fN e p h r o l o g y ,v o l .5 ,n o .7 ,p p .
  29. (2007). N e v e s ,F .G .G r a c i o l l i ,L .M .d o sR e i se ta l . ,“ V a s c u l a r calcification: contribution of parathyroid hormone in renal failure,”
  30. (2010). Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease,”
  31. (2010). Progenitor cells and vascular function are impaired in patients with chronic kidney disease,”
  32. (2006). Protecting the endothelium: a new focus for managementof chronic kidney disease,”
  33. (2011). r u n e t ,B .G o n d o u i n ,A .D u v a l - S a b a t i e r ,L .D o u
  34. (2007). Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro—towards a standardized approach for research on uraemia,”
  35. (2006). S h a h ,E .A .D o m i n i c ,P .M o s e l e ye ta l . ,“ H e m o d i a l y s i s modulates gene expression profile in skeletal muscle,”
  36. (2011). SDF-1α as a therapeutic stem cell homing factor in myocardial infarction,”
  37. (2007). t e n v i n k e l ,M .K a r i m i ,S .J o h a n s s o ne ta l . ,“ I m p a c to fi n -flammation on epigenetic DNA methylation—a novel risk factorforcardiovasculardisease?”JournalofInternalMedicine,
  38. (2003). The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia,”
  39. (2008). The CXCL12γ chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins,”
  40. (2007). The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells,”
  41. (2009). unthner ,V .Jankowski,A.K r etsc hmeretal.,“Endothelium and vascular smooth muscle cells in the context of uremia,”
  42. (2009). Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy,”
  43. (2001). Uremic toxicity: present state of the art,”
  44. (2008). Uremic toxins: what are they? An integrated overview of pathobiology and classification,”